Blancco LFL sales up 40.9% in buoyant market
​Today's results showed group FY15 turnover at £202.6m (+2.6%, or +16.5% in constant currency), headline operating profit of £15.4m (+40%, or +52.7% CCs) and closing net cash at £7.8m. All of these outcomes were in line with our estimates, and this was despite suffering significant forex headwinds (stronger £ vs €, Polish Zloty and other EM currencies). Looking ahead, both YTD trading and the outlook for the remainder of FY16 are said to be "in line with expectations" - with Blancco expanding rapidly and delivering "excellent margins in a buoyant market". FY17 should witness a significant jump in profits, as the drag from the legacy Nokia Europe contract diminishes. Most importantly, the Board also announced that it was "exploring various strategic alternatives, including the potential sale" (or perhaps even spin off) of its Depot Solutions, set-top-box diagnostics and DigitalCare (handset screen insurance) operations .This will help focus attention on Blancco, Regenersis' unique 'data erasure' division. It is the undisputed world leader in this field (>7x bigger than closest rival) which reported: FY15 turnover of £15.0m up 30% (or +40.9% LFL in constant currency), adjusted EBITA of £5.4m and margins of 36%. On its own, we think the software division is worth 166p per diluted share, or more than the market capitalisation of the entire group; based on a 6x FY16 sales multiple for the enlarged software arm (ie including today's $12m acquisition of US rival Tabernus), along with adding another $4.9m for RGS' 49% stake in mobile diagnostics firm Xcaliber.
Regeneus is engaged in the development and commercialization of proprietary adipose-derived stem cell technologies used by physicians and veterinarians to treat musculoskeletal conditions in humans and animals.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.